The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.
Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.
At a NeurologyLive Clinical Forum in Philadelphia, Pennsylvania, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).